NICHOLAS DEPTULA: Open Payments
NPI 1942558036 · WINCHESTER, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,870 in 157 payments from 19 companies in 2025. Trend: 2023 $1,826 · 2024 $8,693 · 2025 $5,870
Food & beverage: $2,678Speaker / faculty: $1,960Travel & lodging: $1,232
| Company | Payments | Amount |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 42 | $3,670 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 17 | $320 |
| ABBVIE INC. | 21 | $291 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $245 |
| Ipsen Biopharmaceuticals, Inc | 5 | $217 |
| Ardelyx, Inc. | 11 | $213 |
| Janssen Biotech, Inc. | 9 | $155 |
| Novo Nordisk Inc | 2 | $148 |
| Gilead Sciences, Inc. | 6 | $137 |
| GENZYME CORPORATION | 5 | $101 |
Products named: VOQUEZNA, XIFAXAN, IBSRELA, ENTYVIO, DUPIXENT, IQIRVO, TREMFYA, Wegovy.
Industry payments across VA — which companies pay providers there.
